Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00536120 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00536120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00536120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2009
Enrollment
60 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis